New genetic test aims to sharpen blood cancer diagnosis
NCT ID NCT07680868
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study looks at a new genetic test called Caris Chromoseq for people with certain blood cancers (acute myeloid leukemia, myelodysplastic syndrome, or myeloproliferative neoplasms). The test scans the entire genome to help classify the cancer and guide risk assessment. Researchers want to see if this test works as well as or better than current methods like cytogenetics, FISH, and NGS. The study involves 300 adults whose doctors have ordered the test, and it will compare results to standard testing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Caris Chromoseq assay
What this could lead to
If successful, this test could provide faster and more detailed genetic information to help doctors classify blood cancers and guide treatment decisions.
What could go wrong
This is an observational study, not a treatment trial. The test's real-world benefits and accuracy compared to existing methods are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- LY3410738 for IDH-Mutant Blood Cancers (NCT04603001)
- Pacritinib + Venetoclax + Azacitidine for MPN-AP NCT07679334
- Vedolizumab for GVHD Prevention Trial (NCT06815003)
- Automated TMLI for HCT in High-Risk Myeloid Canc NCT07634536
- Venetoclax TDM Study in AML | NCT07670130
- ICG415 CAR-T for AML Trial (NCT07668557)
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Caris Life Sciences
RECRUITINGPhoenix, Arizona, 85040, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••